- Home
- CNFR vs KPRX Comparison
CNFR vs KPRX Comparison
Compare CNFR & KPRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CNFR
- KPRX
- Stock Information
- Founded
- CNFR 2009
- KPRX 1998
- Country
- CNFR United States
- KPRX United States
- Employees
- CNFR N/A
- KPRX N/A
- Industry
- CNFR Property-Casualty Insurers
- KPRX Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Sector
- CNFR Finance
- KPRX Health Care
- Exchange
- CNFR Nasdaq
- KPRX Nasdaq
- Market Cap
- CNFR 13.7M
- KPRX 12.0M
- IPO Year
- CNFR 2015
- KPRX N/A
- Fundamental
- Price
- CNFR $1.00
- KPRX $3.47
- Analyst Decision
- CNFR
- KPRX Strong Buy
- Analyst Count
- CNFR 0
- KPRX 1
- Target Price
- CNFR N/A
- KPRX $10.00
- AVG Volume (30 Days)
- CNFR 4.2K
- KPRX 46.3K
- Earning Date
- CNFR 04-03-2025
- KPRX 03-24-2025
- Dividend Yield
- CNFR N/A
- KPRX N/A
- EPS Growth
- CNFR N/A
- KPRX N/A
- EPS
- CNFR 2.40
- KPRX 1.69
- Revenue
- CNFR $74,815,000.00
- KPRX $16,020,000.00
- Revenue This Year
- CNFR N/A
- KPRX N/A
- Revenue Next Year
- CNFR $7.00
- KPRX N/A
- P/E Ratio
- CNFR $0.41
- KPRX $2.05
- Revenue Growth
- CNFR N/A
- KPRX N/A
- 52 Week Low
- CNFR $0.65
- KPRX $3.00
- 52 Week High
- CNFR $1.91
- KPRX $6.75
- Technical
- Relative Strength Index (RSI)
- CNFR 45.41
- KPRX 44.69
- Support Level
- CNFR $0.96
- KPRX $3.40
- Resistance Level
- CNFR $1.07
- KPRX $3.75
- Average True Range (ATR)
- CNFR 0.04
- KPRX 0.22
- MACD
- CNFR 0.01
- KPRX -0.03
- Stochastic Oscillator
- CNFR 47.78
- KPRX 37.65
About CNFR Conifer Holdings Inc.
Conifer Holdings Inc is an insurance company engaged in the sale of property and casualty insurance products. It is engaged in three classes of insurance businesses namely commercial lines, personal lines, and wholesale agency business. Within these three businesses, the company offers various insurance products and insurance agency services. The company views the commercial and personal lines segments as underwriting business. The wholesale agency business provides non-risk bearing revenue through commissions and policy fees. Its revenues are derived from premiums earned from insurance operations.
About KPRX Kiora Pharmaceuticals Inc.
Kiora Pharmaceuticals Inc is a clinical-stage biotechnology company developing and commercializing products for the treatment of orphan retinal diseases. As part of its development, KIO-301 is being studied for the treatment of retinitis pigmentosa, choroideremia, and Stargardt disease. It is a molecular photoswitch that has the potential to restore vision in patients with inherited and/or age-related retinal degeneration. KIO-104 is being developed for the treatment of posterior non-infectious uveitis. It is a next-generation, non-steroidal, immuno-modulatory, and small-molecule inhibitor of dihydroorotate dehydrogenase.